After high-dose chemotherapy followed by HSCT, G-CSF or granulocyte-macrophage colony stimulating factor (GM-CSF) are used to minimize the rates of morbidity and mortality associated with prolonged neutropenia. The gene discussed is CSF3; the disease is neutropenia.